SC
REGN icon

Syon Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Syon Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Sell
857
-164
-16% -$112K 0.02% 602
2026
Q1 		$789K Buy
1,021
+83
+9% +$63.5K 0.04% 385
2025
Q4 		$724K Buy
938
+148
+19% +$101K 0.04% 414
2025
Q3 		$444K Sell
790
-85
-10% -$48.1K 0.02% 532
2025
Q2 		$459K Sell
875
-570
-39% -$318K 0.03% 404
2025
Q1 		$916K Buy
1,445
+162
+13% +$111K 0.07% 194
2024
Q4 		$914K Buy
1,283
+389
+44% +$326K 0.08% 174
2024
Q3 		$940K Sell
894
-8
-0.9% -$8.9K 0.08% 175
2024
Q2 		$948K Buy
902
+13
+1% +$12.6K 0.09% 162
2024
Q1 		$856K Buy
889
+107
+14% +$102K 0.08% 184
2023
Q4 		$687K Buy
782
+168
+27% +$138K 0.07% 192
2023
Q3 		$505K Buy
+614
New +$483K 0.06% 181

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Syon Capital's REGN Position: Q2 2026 in Review

Syon Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2026, selling an estimated $112K and leaving 857 shares worth $534K. The position accounts for 0.02% of the portfolio, ranked #602.

Syon Capital first reported a position in REGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $948K in Q2 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Syon Capital held 857 shares of Regeneron Pharmaceuticals worth $534K as of Q2 2026.
  • Syon Capital sold 164 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $112K.
  • Regeneron Pharmaceuticals made up 0.02% of Syon Capital's portfolio in Q2 2026, its #602 holding.
  • Syon Capital first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Syon Capital's Regeneron Pharmaceuticals position peaked at $948K in Q2 2024.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.